Bolt Biotherapeutics, Inc.

Quarterly Report for period ending 2023-09-30

Quarterly Report for period ending 2023-06-30

Quarterly Report for period ending 2023-03-31

Annual Report for period ending 2022-12-31

Quarterly Report for period ending 2022-09-30

Quarterly Report for period ending 2022-06-30

Quarterly Report for period ending 2022-03-31

Annual Report for period ending 2021-12-31

Quarterly Report for period ending 2021-09-30

Quarterly Report for period ending 2021-06-30

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Annual report to security holders

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Exempt (Private) Offering

Certification by an exchange approving securities for listing

Notice of Effectiveness

None

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)

CITADEL ADVISORS LLC: Major Shareholders

TANG CAPITAL PARTNERS LP: Major Shareholders

Vivo Capital VIII, LLC: Major Shareholders

Pivotal bioVenture Partners Fund I, L.P.: Major Shareholders

Schatzman Randall C: Annual statement of changes in beneficial ownership of securities

Yonehiro Grant: Annual statement of changes in beneficial ownership of securities

Perez Edith A.: Annual statement of changes in beneficial ownership of securities

Quinn William P.: Statement of changes in beneficial ownership of securities

ENGLEMAN EDGAR: Statement of changes in beneficial ownership of securities

ENGLEMAN EDGAR: Statement of changes in beneficial ownership of securities

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Prospectus filed pursuant to Rule 424(b)(5)

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Registration statement for specified transactions by certain issuers

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Prospectus filed pursuant to Rule 424(b)(4)

A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statements

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statements